Mucopolysaccharidoses in the Scandinavian countries: incidence and prevalence

被引:90
作者
Malm, Gunilla [1 ]
Lund, Allan M. [2 ]
Mansson, Jan-Eric [3 ]
Heiberg, Arvid [4 ]
机构
[1] Karolinska Univ Hosp, Karolinska Inst, Div Paediat, Dept Clin Sci Intervent & Technol, Huddinge, Sweden
[2] Copenhagen Univ Hosp, Dept Clin Genet, Juliane Marie Ctr, Copenhagen, Denmark
[3] Sahlgrenska Univ Hosp Molndal, Dept Psychiat & Neurochem, Inst Neurosci & Physiol, Gothenburg, Sweden
[4] Univ Oslo, Rikshosp, Dept Med Genet, N-0027 Oslo, Norway
关键词
Incidence; Mucopolysaccharidoses; Prevalence; Scandinavia;
D O I
10.1111/j.1651-2227.2008.00965.x
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Aim: The aim of this study was to estimate the incidence and prevalence of mucopolysaccharidoses (MPS disorders) in Scandinavia. Methods: The retrospective period used for the incidence study covered the period from 1975 to 2004 in Sweden and Denmark and from 1979 to 2004 in Norway. Prevalence was derived from the number of MPS patients alive as of December 31, 2007. Results: The incidence of all MPS disorders was 1.75 cases in Sweden, 3.08 cases in Norway and 1.77 cases in Denmark per 100 000 newborns. The incidence of MPS I was the most common in all three countries, with 0.67, 1.85 and 0.54 cases per 100 000 newborns, respectively; for MPS 11, numbers were 0.27, 0.13 and 0.27, respectively. For patients with other MPS disorders the incidence varied widely. The prevalence for all MPS disorders was 4.24, 7.06 and 6.03 per 1 000 000 inhabitants in Sweden, Norway and Denmark, respectively. Conclusion: From three Scandinavian countries the incidence of MPS disorders is retrospectively evaluated for 25 years in Norway and 30 years in Sweden and Denmark. Incidence and prevalence studies of lysosomal disorders are prerequisites for cost benefit calculations in the face of newly developed and expensive therapies in the future.
引用
收藏
页码:1577 / 1581
页数:5
相关论文
共 22 条
[1]   Cumulative incidence rates of the mucopolysaccharidoses in Germany [J].
Baehner, F ;
Schmiedeskamp, C ;
Krummenauer, F ;
Miebach, E ;
Bajbouj, M ;
Whybra, C ;
Kohlschütter, A ;
Kampmann, C ;
Beck, M .
JOURNAL OF INHERITED METABOLIC DISEASE, 2005, 28 (06) :1011-1017
[2]  
Beesley CE, 2001, HUM GENET, V109, P503
[3]   Long-term outcomes of adaptive functions for children with mucopolysaccharidosis I (Hurler syndrome) treated with hematopoietic stem cell transplantation [J].
Bjoraker, Kendra J. ;
Delaney, Kathleen ;
Peters, Charles ;
Krivit, William ;
Shapiro, Elsa G. .
JOURNAL OF DEVELOPMENTAL AND BEHAVIORAL PEDIATRICS, 2006, 27 (04) :290-296
[4]   Outcomes of hematopoietic stem cell transplantation for Hurler's syndrome in Europe: a risk factor analysis for graft failure [J].
Boelens, J. J. ;
Wynn, R. F. ;
O'Meara, A. ;
Veys, P. ;
Bertrand, Y. ;
Souillet, G. ;
Wraith, J. E. ;
Fischer, A. ;
Cavazzana-Calvo, M. ;
Sykora, K. W. ;
Sedlacek, P. ;
Rovelli, A. ;
Uiterwaal, C. S. P. M. ;
Wulffraat, N. .
BONE MARROW TRANSPLANTATION, 2007, 40 (03) :225-233
[5]   Safety and efficacy of enzyme replacement therapy in combination with hematopoietic stem cell transplantation in Hurler syndrome [J].
Grewal, SS ;
Wynn, R ;
Abdenur, JE ;
Burton, BK ;
Gharib, M ;
Haase, C ;
Hayashi, RJ ;
Shenoy, S ;
Sillence, D ;
Tiller, GE ;
Dudek, ME ;
van Royen-Kerkhof, A ;
Wraith, JE ;
Woodard, P ;
Young, GA ;
Wulffraat, N ;
Whitley, CB ;
Peters, C .
GENETICS IN MEDICINE, 2005, 7 (02) :143-146
[6]   Direct comparison of measures of endurance, mobility, and joint function during enzyme-replacement therapy of mucopolysaccharidosis VI (Maroteaux-Lamy syndrome):: Results after 48 weeks in a phase 2 open-label clinical study of recombinant human N-acetylgalactosamine 4-sulfatase [J].
Harmatz, P ;
Ketteridge, D ;
Giugliani, R ;
Guffon, N ;
Teles, EL ;
Miranda, MCS ;
Yu, ZF ;
Swiedler, SJ ;
Hopwood, JJ .
PEDIATRICS, 2005, 115 (06) :E681-E689
[7]   FLUOROMETRIC ASSAY USING 4-METHYLUMBELLIFERYL ALPHA-L-IDURONIDE FOR THE ESTIMATION OF ALPHA-L-IDURONIDASE ACTIVITY AND THE DETECTION OF HURLER AND SCHEIE SYNDROMES [J].
HOPWOOD, JJ ;
MULLER, V ;
SMITHSON, A ;
BAGGETT, N .
CLINICA CHIMICA ACTA, 1979, 92 (02) :257-265
[8]   Long-term and high-dose trials of enzyme replacement therapy in the canine model of mucopolysaccharidosis [J].
Kakkis, ED ;
McEntee, MF ;
Schmidtchen, A ;
Neufeld, EF ;
Ward, DA ;
Gompf, RE ;
Kania, S ;
Bedolla, C ;
Chien, SL ;
Shull, RM .
BIOCHEMICAL AND MOLECULAR MEDICINE, 1996, 58 (02) :156-167
[9]   Enzyme-replacement therapy in mucopolysaccharidosis I. [J].
Kakkis, ED ;
Muenzer, J ;
Tiller, GE ;
Waber, L ;
Belmont, J ;
Passage, M ;
Izykowski, B ;
Phillips, J ;
Doroshow, R ;
Walot, I ;
Hoft, R ;
Yu, KT ;
Okazaki, S ;
Lewis, D ;
Lachman, R ;
Thompson, JN .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (03) :182-188
[10]  
Krivit William, 2002, Adv Pediatr, V49, P359